← Leaderboards
John Lacava
Cdi Laboratories, Inc.
$4,805,474
Attributed
$7,344,034
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,344,034 · 5
By mechanism
R01$6,999,714 · 3
R41$294,320 · 1
R13$50,000 · 1
Top collaborators
- John M. Sedivy4 shared
- Joanne Michelle Kahlenberg2 shared
- Tomas M Mustelin2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCellsProteinsMolecularSamplingTissuesMass Spectrum AnalysisFunctional DisorderPhysiologicalIn VitroHybridsTechnologyBiologicalProductionLocationRetrotransposonComputerized ToolsPlayPathway InteractionsPreventGenesDouble-Stranded RnaExhibitsDetection
Grant awards (15)
Upstream drivers of type I interferons in lupus$758,431
R01 · FY2025 · AI
Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD$731,293
R01 · FY2025 · AG · contact PI
Mobile DNA: Mechanisms and Health Impact$50,000
R13 · FY2025 · AG · contact PI
Upstream drivers of type I interferons in lupus$796,681
R01 · FY2024 · AI
Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD$746,218
R01 · FY2024 · AG · contact PI
Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD$746,218
R01 · FY2023 · AG · contact PI
Defining molecular contributions of LINE-1 retrotransposons to AD / ADRD$779,909
R01 · FY2022 · AG · contact PI
An integrated pipeline for next-generation protein interactomics$502,852
R01 · FY2021 · GM · contact PI
An integrated pipeline for next-generation protein interactomics$502,852
R01 · FY2020 · GM · contact PI
Demonstrating interactome-level connections between Alzheimer disease, LINE-1 retrotransposons, and cellular senescence$191,455
R01 · FY2020 · GM · contact PI
An integrated pipeline for next-generation protein interactomics$502,852
R01 · FY2019 · GM · contact PI
An integrated pipeline for next-generation protein interactomics$94,351
R01 · FY2019 · GM · contact PI
An integrated pipeline for next-generation protein interactomics$520,227
R01 · FY2018 · GM · contact PI
An integrated pipeline for next-generation protein interactomics$126,375
R01 · FY2018 · GM · contact PI
Monospecific monoclonal antibodies against human protein complexes on an interactome-wide scale.$294,320
R41 · FY2016 · CA · contact PI